Companies Dashboard

Overview

This dashboard provides a comprehensive statistical overview of pharmaceutical and biotech companies actively developing treatments for neurodegenerative diseases in NeuroWiki. It serves as a central hub for understanding the therapeutic landscape, company capabilities, and development pipelines.

Summary Statistics

| Metric | Value |
|--------|-------|
| Total Company Pages | 198[@neurowiki2026] |
| Companies with AD Programs | 87[@neurowiki2026] |
| Companies with PD Programs | 72[@neurowiki2026] |
| Companies with ALS Programs | 45[@neurowiki2026] |
| Companies with FTD Programs | 28[@neurowiki2026] |
| Clinical-Stage Companies | 94 |
| Preclinical/Discovery | 104 |

Company Distribution by Focus Area

Alzheimer's Disease (AD)

The largest therapeutic area in neurodegeneration, with 87 companies developing treatments targeting [amyloid-beta](/proteins/amyloid-beta), [tau](/proteins/tau), neuroinflammation, and other mechanisms.

Key Companies:

• [Biogen](/companies/biogen) — Leqembi (lecanemab), Aduhelm
• [Eli Lilly](/companies/eli-lilly) — Kisunla (donanemab)
• [Eisai](/companies/eisai) — Leqembi partnership
• [Roche](/companies/roche) — Gantenerumab, Trontinemab
• [AC Immune](/companies/ac-immune) — Tau vaccines, [alpha-synuclein](/proteins/alpha-synuclein)

Parkinson's Disease (PD)

72 companies focusing on alpha-synuclein, [LRRK2](/entities/lrrk2), [GBA1](/entities/gba), and mitochondrial dysfunction.

...

Overview

This dashboard provides a comprehensive statistical overview of pharmaceutical and biotech companies actively developing treatments for neurodegenerative diseases in NeuroWiki. It serves as a central hub for understanding the therapeutic landscape, company capabilities, and development pipelines.

Summary Statistics

| Metric | Value |
|--------|-------|
| Total Company Pages | 198[@neurowiki2026] |
| Companies with AD Programs | 87[@neurowiki2026] |
| Companies with PD Programs | 72[@neurowiki2026] |
| Companies with ALS Programs | 45[@neurowiki2026] |
| Companies with FTD Programs | 28[@neurowiki2026] |
| Clinical-Stage Companies | 94 |
| Preclinical/Discovery | 104 |

Company Distribution by Focus Area

Alzheimer's Disease (AD)

The largest therapeutic area in neurodegeneration, with 87 companies developing treatments targeting [amyloid-beta](/proteins/amyloid-beta), [tau](/proteins/tau), neuroinflammation, and other mechanisms.

Key Companies:

• [Biogen](/companies/biogen) — Leqembi (lecanemab), Aduhelm
• [Eli Lilly](/companies/eli-lilly) — Kisunla (donanemab)
• [Eisai](/companies/eisai) — Leqembi partnership
• [Roche](/companies/roche) — Gantenerumab, Trontinemab
• [AC Immune](/companies/ac-immune) — Tau vaccines, [alpha-synuclein](/proteins/alpha-synuclein)

Parkinson's Disease (PD)

72 companies focusing on alpha-synuclein, [LRRK2](/entities/lrrk2), [GBA1](/entities/gba), and mitochondrial dysfunction.

Key Companies:

• [Biogen](/companies/biogen) — BIIB122 (LRRK2 inhibitor)
• [Roche](/companies/roche) — Ricobendazole
• [Denali Therapeutics](/companies/denali) — LRRK2, GBA1 programs
• [Prothena](/companies/prothena) — Tau and alpha-synuclein

Amyotrophic Lateral Sclerosis (ALS)

45 companies targeting SOD1, [C9orf72](/entities/c9orf72), [TDP-43](/mechanisms/tdp-43-proteinopathy), and neuroprotection mechanisms.

Key Companies:

• [Biogen](/companies/biogen) — Tofersen (SOD1)
• [AbbVie](/companies/abbvie) — Multiple ALS programs
• [Amylyx](/companies/amylyx-pharmaceuticals) — AMX0035

Frontotemporal Dementia (FTD)

28 companies developing treatments for tau, TDP-43, and progranulin.

Development Stage Distribution

| Stage | Companies |
|-------|-----------|
| Phase 3 | 12 |
| Phase 2 | 28 |
| Phase 1 | 31 |
| Preclinical | 67 |
| Discovery | 52 |

Technology Platforms

Antibody-Based Therapies

Companies leveraging monoclonal antibodies for target engagement.

Gene Therapy / RNA Targeting

Companies using AAV vectors, ASOs, and RNAi for genetic interventions.

Small Molecule Inhibitors

Traditional pharmaceutical approaches targeting enzymes and receptors.

Cell Therapy

Companies developing stem cell or cellular replacement approaches.

Company Rankings

By Pipeline Depth

[Biogen](/companies/biogen) — 8+ neurodegeneration programs

[Roche](/companies/roche) — 6+ programs

[Eli Lilly](/companies/eli-lilly) — 5+ programs

[Denali Therapeutics](/companies/denali) — 4+ programs

[AbbVie](/companies/abbvie) — 4+ programs

By Innovation Score

Based on mechanism novelty, target diversity, and delivery approaches.

Pipeline Highlights

Late-Stage Programs (Phase 2/3)

| Drug | Company | Mechanism | Indication |
|------|---------|-----------|------------|
| Leqembi | Biogen/Eisai | Anti-Aβ antibody | AD |
| Kisunla | Eli Lilly | Anti-Aβ antibody | AD |
| BIIB122 | Biogen | LRRK2 inhibitor | PD |
| Trontinemab | Roche | Brain-penetrant anti-Aβ | AD |

Related Pages

• [Companies Index](/companies) — Full company directory
• [AD Pipeline Companies](/companies/ad-pipeline-companies) — Alzheimer's programs
• [PD Pipeline Companies](/companies/pd-pipeline-companies) — Parkinson's programs
• [Clinical Trials Overview](/clinical-trials/overview) — Trial landscape

Data Sources

• NeuroWiki company database
• ClinicalTrials.gov
• Company pipelines and press releases

Last updated: 2026-03-17

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

Unknown, NeuroWiki Company Database. Company pages and therapeutic program data. Accessed 2026-03-17. Available at: (2026)

Unknown, ClinicalTrials.gov (2026)

Unknown, Alzheimer's Association Facts and Figures 2024 (2024)

Unknown, Parkinson's Foundation Statistics (2024)

Unknown, amyotrophic Lateral Sclerosis Association (2024)